Breaking News

Rho Selected by HHS for CRO Network

By Kristin Brooks | March 27, 2014

To facilitate medical countermeasure product development

Rho’s Federal Systems Division has been selected by the U.S. Department of Health and Human Services (HHS) to be part of a network of five CROs to design and conduct clinical studies for the development of medical countermeasures, including drugs, vaccines and diagnostic tests that help protect public health against bioterrorism, pandemic influenza, and other health emergencies. 
 
The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will manage the new clinical studies network, and Rho will support targeted clinical studies relevant to BARDA's goals to quickly and effectively respond to deliberate, natural and emerging threats by providing a range of clinical study services that can be used by BARDA and its development partners.
 
Clinical studies will include trials evaluating chemical, biological, radiological, nuclear (CBRN), pandemic influenza and/or emerging infectious disease medical countermeasures. Also, clinical trial response readiness projects will address preparedness and response activities in advance of a public health emergency and may require the development and implementation of a detailed plan for the initiation of clinical studies within a certain timeframe.  
 
“We are honored to have Rho’s Federal Systems Division selected by HHS to be a part of this clinical studies network,” said Russ Helms, Ph.D., chief executive officer at Rho. “This appointment reflects our team’s expertise and leadership in this field of research.”

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.